Abstracts Archive - Page 619 of 2607 - ACR Meeting Abstracts

Abstract Number: 2045 • ACR Convergence 2022
Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
Maxime Beydon¹, Marie Dulin², Raphaèle Seror³, Frederic Desmoulins², Xavier Mariette⁴ and Gaetane Nocturne⁵, ¹Université Paris Cité, Paris, France, ²Kremlin Bicêtre Hospital - APHP, Paris, France, ³University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁵APHP, Le Kremlin Bicêtre, France
Background/Purpose: It is well established that in systemic lupus erythematous (SLE), disease burden is higher in patients from African ancestry (AA) than in Caucasian patients.…
Abstract Number: 2040 • ACR Convergence 2022
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Astrid Rasmussen¹, R. Hal Scofield², Kiely Grundahl¹, Lida Radfar², Christopher Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
Abstract Number: 2036 • ACR Convergence 2022
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
Andres Martinez¹, Julieta Morbiducci¹, Constanza Arguissain¹, Maria Tamborenea¹, Marisel Bejarano², Lucia Castorino¹ and Anastasia Secco¹, ¹Rivadavia Hospital, Buenos Aires, Argentina, ²Rivadavia´s Hospital, Buenos Aires, Argentina
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
Abstract Number: 2050 • ACR Convergence 2022
Stratification on Baseline Interferon Scores and Use of CRESS to Improve the Design of Future Trials in Sjögren’s Syndrome: Post Hoc Analysis from a Randomized Controlled Trial
jacques-eric gottenberg¹, Bryan Downie², Oksana Gurtovaya² and Anubhav Mathur², ¹Strasbourg University Hospital, Strasbourg, France, ²Gilead Sciences, Foster City, CA
Background/Purpose: A multicenter, global, randomized, Phase 2, double-blind, placebo (PBO)-controlled study showed filgotinib (FIL; 200 mg/d), lanraplenib (LAN; 30 mg/d), and tirabrutinib (TIRA; 40 mg/d)…
Abstract Number: 2049 • ACR Convergence 2022
ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Phoung Phoung Diep¹, Karoline Lerang², Birgir Gudbransson¹, Helena Andersson¹, Øyvind Midtvedt¹, Torhild Garen¹, Michael Durheim¹, Trond Mogens Aaløkken¹, Øyvind Palm¹ and Øyvind Molberg², ¹Oslo University Hospital, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
Abstract Number: 2046 • ACR Convergence 2022
Agreement Between Labial Biopsy and the OMERACT Grey-scale Ultrasound Scoring System for Salivary Glands in a Single-center Cohort of Patients with Suspected Sjögren’s Syndrome
Viktoria Fana¹, Nanna Surlemont Schmidt², Uffe Møller Døhn¹, Simon Krabbe³ and Lene Terslev⁴, ¹Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet, Copenhagen, Denmark, ³Rigshospitalet, København, Denmark, ⁴Copenhagen University Hospital Glostrup, Glostrup, Denmark
Background/Purpose: Ultrasound is a promising non-invasive tool in the evaluation of the salivary glands for parenchymal changes related to Sjögrens Syndrome (SS). The OMERACT Ultrasound…
Abstract Number: 2047 • ACR Convergence 2022
Discriminative Power of Salivary Gland Ultrasound in Relation to Symptom-based Endotypes in Suspected and Definite Primary Sjögren’s Syndrome
Liselotte Deroo¹, Helena Achten², Eva Genbrugge², Wouter Bauters², Dimitri Roels², Frederick Dochy², David Creytens², Ann-Sophie Kathleen De Craemer², Filip Van den bosch³, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Gent, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁴Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁵Ghent University Hospital, Ghent, Belgium
Background/Purpose: Primary Sjögren's Syndrome (pSS) is characterized by xerophthalmia, xerostomia and increased lymphoma risk. To address heterogeneity in symptoms, Tarn et al. applied cluster analysis…
Abstract Number: 2057 • ACR Convergence 2022
Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
Meghan Nelson¹, Colleen Mosley², D. Sofia Villacis-Nunez³, Kelly Rouster-Stevens³ and Amit Thakral³, ¹Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children's Healthcare of Atlanta, Atlanta, GA, ²Children’s Healthcare of Atlanta, Atlanta, GA, ³Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that is associated with significant disease damage, morbidity, and mortality. In comparison to the adult…
Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Takehiro Nakai¹, Sho Fukui², Takahiro Asano³, Futoshi Iwata⁴, Hiroki Ozawa⁵, Satoshi Kawaai⁴, Yukihiko Ikeda¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁶, Kenichi YAMAGUCHI⁷ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Kyorin University Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo City Tokyo, Japan, ⁴St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
Abstract Number: 2037 • ACR Convergence 2022
Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype
Lucia Martin-Gutierrez¹, Hannah Peckham², Anna Radziszewska², Junjie Peng², Oluwatomisin Nettey², Elizabeth Jury³ and Coziana Ciurtin⁴, ¹Centre for Rheumatology Research, Department of Medicine,University College London, London, ²Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, ³University College London, London, United Kingdom, ⁴Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune rheumatic disease characterised by dryness resulting from chronic lymphocytic infiltration of the exocrine glands and extra glandular manifestations…
Abstract Number: 2061 • ACR Convergence 2022
Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
Dafna Gladman¹, KONSTANTINOS TSELIOS², Jiandong Su³ and Murray Urowitz⁴, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) affects up to 40% of patients with SLE and leads to end stage kidney disease (ESKD) in 17-33% after 10 years.…
Abstract Number: 2062 • ACR Convergence 2022
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Sandra Sze-jung Wu¹, Allison Perry², Nicole Zimmerman³, Helen Varker⁴, Rich Bizier⁴, Liisa Palmer⁴, Christine Dube⁵ and Gary Bryant⁶, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³IBM Watson Health, Chagrin Falls, OH, ⁴Merative, Cambridge, MA, ⁵AstraZeneca, Torrington, CT, ⁶AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an…
Abstract Number: 2053 • ACR Convergence 2022
Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Pamela Munguía-Realpozo², David Angel Osorio-Peña², Socorro Méndez-Martínez¹ and Mario Garcia-Carrasco², ¹Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: There is increased interest in machine learning (ML)-based prediction models in systemic lupus erythematosus (SLE). We made a systematic review of adherence in diagnostic…
Abstract Number: 2054 • ACR Convergence 2022
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Kathryn Connelly¹, Laura Eades², Rachel Koelmeyer³, Darshini Ayton³, Vera Golder², Rangi Kandane-Rathnayake², Kate Gregory-Wong³, Hussein Al-Mossawi⁴, Jeanette Andersen⁵, Cynthia Aranow⁶, Laurent Arnaud⁷, Anca Askanase⁸, Subhashis Banerjee⁹, Catherine Barbey¹⁰, Hermine Brunner¹¹, Joy Buie¹², Laurie Burke¹³, Alain Cornet¹⁴, Karen Costenbader¹⁵, Maria Dall'Era¹⁶, Khadija Dantata¹⁷, Nikolay Delev⁹, Ann Eldred¹⁸, Alan Friedman¹⁹, Richard Furie²⁰, Sandra Garces²¹, Dennis Grasela²², Heath Guay²³, Oliver Guenther²⁴, Maria Juarez²⁵, Shelly Kafka²⁶, Kenneth Kalunian²⁷, Elaine Karis²⁸, Youmna Lahoud²⁹, Catharina Lindholm³⁰, Jeffrey Lockman³¹, Charlotte Lupton³², Justine Maller³³, Ashley Marion³⁴, Patrick Marquis³⁵, Joan Merrill³⁶, Thomas Morel³⁷, Marta Mosca³⁸, Yulia Pincus³⁹, Samantha Pomponi⁴⁰, Guillermo Pons-Estel⁴¹, Jorge Ross Terres³³, Cailin Sibley⁴², Maria Silk⁴³, Sanjeev Roy⁴⁴, Lee S Simon⁴⁵, Alessandro Sorrentino⁴⁶, Christian Stach⁴⁷, George Stojan⁴⁸, Ying Sun²⁴, Yoshiya Tanaka⁴⁹, Erik Thomas⁵⁰, Ronald van Vollenhoven⁵¹, Cristina Vazquez Mateo⁵⁰, Edward M Vital⁵², Victoria Werth⁵³, Eric Zollars²⁸, Qing Zuraw⁵⁴ and Eric Morand⁵⁵, ¹Monash Health, Camberwell, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia, ⁴AstraZeneca, Bucks, United Kingdom, ⁵Lupus Europe, Lupus DK, EULAR PARE, ERN ReCONNECT, Brussels, Belgium, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, ⁸Columbia University Medical Center, New York, NY, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Biogen, Baar, Switzerland, ¹¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ¹²Lupus Foundation of America, Charleston, SC, ¹³LORA Group, Royal Oak, MD, ¹⁴Lupus Europe, Brussels, Belgium, ¹⁵Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, Division of Rheumatology, San Francisco, CA, ¹⁷Lupus Foundation of America, Richmond Hill, GA, ¹⁸AbbVie, Inc., Lake Bluff, IL, ¹⁹AbbVie, Inc., Libertyville, IL, ²⁰Northwell Health, Great Neck, NY, ²¹Amgen, Inc., Almada, Portugal, ²²Bristol Myers Squibb, Lawrencevile, NJ, ²³AbbVie, Inc., Worcester, MA, ²⁴Merck KGaA, Darmstadt, Germany, ²⁵UCB Pharma, Slough, United Kingdom, ²⁶AbbVie, Inc., Norristown, PA, ²⁷University of California San Diego, La Jolla, CA, ²⁸Amgen, Inc., Thousand Oaks, CA, ²⁹Biogen International GmbH, Milton, MA, ³⁰AstraZeneca, Gothenburg, Sweden, ³¹Bristol-Myers Squibb, New York, NY, ³²AstraZeneca, Cambridge, United Kingdom, ³³Genentech, San Francisco, CA, ³⁴Lupus Foundation of America, Washington, DC, ³⁵Modus Outcomes, Cambridge, MA, ³⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ³⁷UCB Pharma, Brussels, Belgium, ³⁸University of Pisa, Pisa, Italy, ³⁹Janssen, Flemington, NJ, ⁴⁰Bristol Myers Squibb, Lawrence Township, NJ, ⁴¹Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ⁴²Janssen Research & Development, San Diego, CA, ⁴³Eli Lilly, Carmel, IN, ⁴⁴Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany,⁴⁵SDG LLC, West Newton, MA,⁴⁶AstraZeneca, Sollentuna, Sweden, ⁴⁷UCB Pharma, Monheim, ⁴⁸UCB Pharma, Baltimore, MD, ⁴⁹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵⁰EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁵¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵⁴Janssen Research and Development, LLC, Spring House, PA, ⁵⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory…
Abstract Number: 1643 • ACR Convergence 2022
Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK
Subhashisa Swain¹, Carol Coupland², Anne Kamps³, Jos Runhaar⁴, Andrea Dell ‘Isola⁵, Aleksandra Turkiewicz⁵, Danielle E Robinson¹, Victoria Y Strauss¹, Christian Mallen⁶, Chang-Fu Kuo⁷, Aliya Sarmanova⁸, Daniel Prieto Alhambra¹, Martin Englund⁵, Sita Bierma-Zeinstra³, Michael Doherty² and Weiya Zhang², ¹University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Erasmus University Medical Centre, Rotterdam, Netherlands, ⁴Erasmus Medical Center, Rotterdam, Netherlands, ⁵Lund University, Lund, Sweden, ⁶Keele University, Keele, United Kingdom, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Bristol, Bristol, United Kingdom
Background/Purpose: People with osteoarthritis (OA) often have multiple other conditions (comorbidities).Role of different oral analgesics on the development of comorbidities in people with OA have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].